共 31 条
Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B
被引:503
作者:
Yuen, Man-Fung
[1
]
Tanaka, Yasuhito
[2
]
Fong, Daniel Yee-Tak
[3
]
Fung, James
[1
]
Wong, Danny Ka-Ho
[1
]
Yuen, John Chi-Hang
[1
]
But, David Ylu-Kuen
[1
]
Chan, Annie On-On
[1
]
Wong, Benjamin Chun-Yu
[1
]
Mjzokami, Masashi
[2
]
Lai, Ching-Lung
[1
]
机构:
[1] Univ Hong Kong, Queen Mary Hosp, Dept Med, Hong Kong, Hong Kong, Peoples R China
[2] Nagoya City Univ, Grad Sch Med Sci, Dept Clin Mol Informat Med, Nagoya, Aichi, Japan
[3] Univ Hong Kong, Queen Mary Hosp, Dept Nursing Studies, Hong Kong, Hong Kong, Peoples R China
关键词:
Chronic hepatitis B;
Hepatocellular carcinoma;
Risk factor;
Prediction;
BASAL CORE PROMOTER;
VIRUS GENOTYPE-B;
E-ANTIGEN;
PRECORE MUTATIONS;
LIVER-DISEASE;
VIRAL LOAD;
DNA LEVELS;
HONG-KONG;
INFECTION;
CARRIERS;
D O I:
10.1016/j.jhep.2008.07.023
中图分类号:
R57 [消化系及腹部疾病];
学科分类号:
摘要:
Background/Aims: To determine whether gender, age, hepatitis B virus genotype, core promoter and precore mutations, HBeAg/anti-HBe status, HBV DNA, ALT levels and cirrhosis on presentation were independent risk factors and derive a novel risk score for the development of HCC. Methods: CHB patients (820) were followed up (mean duration 76.8 months) for the occurrence of HCC. Results: The 5- and 10-year prevalence of HCC were 4.4% and 6.3%, respectively. Cox regression analysis showed that male gender (p = 0.025, RR 2.98), increasing age (p < 0.001, RR 1.07), higher HBV DNA levels (p = 0.02, RR 1.28), core promoter mutations (p = 0.007, RR 3.66), and presence of cirrhosis (p < 0.001, RR 7.31) were independent risks for the development of HCC. A risk score was derived and validated with sensitivity > 84% and specificity > 76% to predict the 5- and 10-year risks for the development of HCC. The AUC for the 5- and 10-year prediction were 0.88 and 0.89, respectively. Conclusions:The risk score, based on age, gender, HBV DNA levels, core promoter mutations and cirrhosis, can estimate the chance of development of HCC in 5 and 10 years after presentation. It can be used to identify high-risk CHB patients for treatment and screening of HCC. (C) 2008 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:80 / 88
页数:9
相关论文